Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Malignant Melanoma

  Free Subscription


Articles published in N Engl J Med

Retrieve available abstracts of 23 articles:
HTML format



Single Articles


    January 2024
  1. MOHAREB AM, Kang J, Montazeri K, Shroff SG, et al
    Case 2-2024: A 57-Year-Old Woman with Melanoma and Fever.
    N Engl J Med. 2024;390:255-265.
    PubMed    


    October 2023
  2. HASSEL JC, Piperno-Neumann S, Rutkowski P, Baurain JF, et al
    Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma.
    N Engl J Med. 2023 Oct 21. doi: 10.1056/NEJMoa2304753.
    PubMed     Abstract available


    May 2023
  3. WEN L, Cai L
    Primary Diffuse Meningeal Melanomatosis.
    N Engl J Med. 2023;388:1892.
    PubMed    


    March 2023
  4. ROHAAN MW, Kessels R, Haanen JBAG
    Tumor-Infiltrating Lymphocyte Therapy in Advanced Melanoma. Reply.
    N Engl J Med. 2023;388:859-860.
    PubMed    


  5. LIM AR, Shin SW
    Tumor-Infiltrating Lymphocyte Therapy in Advanced Melanoma.
    N Engl J Med. 2023;388:859.
    PubMed    


  6. PATEL SP, Othus M, Chen Y, Wright GP Jr, et al
    Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma.
    N Engl J Med. 2023;388:813-823.
    PubMed     Abstract available


    December 2022
  7. ROHAAN MW, Borch TH, van den Berg JH, Met O, et al
    Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma.
    N Engl J Med. 2022;387:2113-2125.
    PubMed     Abstract available


    June 2022
  8. ROKHZAN R, Meier K
    Targeted Therapy in Melanoma.
    N Engl J Med. 2022;386:e66.
    PubMed    


    May 2022
  9. TAWBI HA, Hodi FS, Long GV
    Nivolumab with or without Relatlimab in Untreated Advanced Melanoma. Reply.
    N Engl J Med. 2022;386:1860-1861.
    PubMed    


  10. HINDIE E
    Nivolumab with or without Relatlimab in Untreated Advanced Melanoma.
    N Engl J Med. 2022;386:1860.
    PubMed    


    March 2022
  11. ZHANG P, Chen L
    Melanoma of the Palpebral Conjunctiva and Eyelid.
    N Engl J Med. 2022 Mar 19. doi: 10.1056/NEJMicm2115699.
    PubMed    


    February 2022
  12. WING JR, Kimball A, Rengarajan M
    Case 6-2022: A 68-Year-Old Man with Fatigue, Weight Loss, and Hyperglycemia.
    N Engl J Med. 2022;386:781-787.
    PubMed    


  13. MCGARRITY TJ
    Roulette.
    N Engl J Med. 2022;386:505-507.
    PubMed    


    January 2022
  14. FRAMPTON AE, Sivakumar S
    A New Combination Immunotherapy in Advanced Melanoma.
    N Engl J Med. 2022;386:91-92.
    PubMed    


  15. TAWBI HA, Schadendorf D, Lipson EJ, Ascierto PA, et al
    Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma.
    N Engl J Med. 2022;386:24-34.
    PubMed     Abstract available


    November 2021
  16. VARONI EM, Decani S
    Gingival Melanoma.
    N Engl J Med. 2021;385:e73.
    PubMed    


    September 2021
  17. NATHAN P, Hassel JC, Rutkowski P, Baurain JF, et al
    Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma.
    N Engl J Med. 2021;385:1196-1206.
    PubMed     Abstract available


    June 2021
  18. CURTI BD, Faries MB
    Recent Advances in the Treatment of Melanoma.
    N Engl J Med. 2021;384:2229-2240.
    PubMed    


    April 2021
  19. ADAMSON AS, Mazer BL, Welch HG
    The Rapid Rise in Cutaneous Melanoma Diagnoses. Reply.
    N Engl J Med. 2021;384:e54.
    PubMed    


  20. GOLDSMITH SM
    The Rapid Rise in Cutaneous Melanoma Diagnoses.
    N Engl J Med. 2021;384:e54.
    PubMed    


  21. GROSSMAN D, Sweeney C, Doherty JA
    The Rapid Rise in Cutaneous Melanoma Diagnoses.
    N Engl J Med. 2021;384:e54.
    PubMed    


    January 2021
  22. WELCH HG, Mazer BL, Adamson AS
    The Rapid Rise in Cutaneous Melanoma Diagnoses.
    N Engl J Med. 2021;384:72-79.
    PubMed    


    December 2020
  23. LEMAITRE S, Arora A
    Iridociliary Melanoma.
    N Engl J Med. 2020;383:e133.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Malignant Melanoma is free of charge.